Understanding India’s National Immunization Schedule
India’s National Immunization Schedule (NIS), updated by the Ministry of Health and Family Welfare (MoHFW) in 2023 and aligned with the Indian Academy of Pediatrics (IAP) Advisory Committee on Vaccines and Immunization Practices (ACVIP) 2023 guidelines, provides a scientifically validated roadmap to protect children from 12 life-threatening infectious diseases. The schedule begins at birth and extends through age five, integrating fixed-dose combinations, temperature-stable formulations, and newly introduced vaccines like Pneumococcal Conjugate Vaccine (PCV) and Inactivated Polio Vaccine (IPV). Unlike static global benchmarks, India’s NIS accounts for regional disease burden, cold-chain infrastructure limitations, and high-burden co-infections such as tuberculosis and malnutrition. As of April 2024, over 92% of Indian infants receive at least three doses of Diphtheria-Tetanus-Pertussis (DTP) vaccine, according to the latest District Level Household Survey (DLHS-5) data. This article details exact timings, licensed vaccine brands, administration routes, storage requirements, and evidence-backed strategies to address missed doses—offering actionable clarity for parents, anganwadi workers, pediatricians, and ASHA functionaries.
Vaccines Administered From Birth Through 14 Weeks
The first 14 weeks represent the most critical immunization window, covering six essential antigens across eight scheduled contacts. At birth, every newborn receives Bacillus Calmette–Guérin (BCG) vaccine — administered intradermally in the left upper arm — and the first dose of Hepatitis B (HepB1) within 24 hours. BCG is supplied exclusively as a lyophilized powder reconstituted with 1 mL sterile water; the WHO-prequalified brand used nationally is Serum Institute of India’s (SII) ‘BCG-Moreau’ strain (batch potency ≥ 3 × 105 CFU/dose). HepB1 is given as a 0.5 mL intramuscular injection using either SII’s ‘Recombivax HB’ (10 µg antigen/dose) or Bharat Biotech’s ‘Elohexa’ (10 µg/dose). Both require refrigeration at +2°C to +8°C and have a shelf life of 36 months unopened.
6-Week Milestone: The First Pentavalent Dose
At exactly 6 weeks of age — not earlier than 42 days — infants receive the first dose of the pentavalent vaccine (DTP-HepB-Hib), alongside Oral Polio Vaccine (OPV) and Rotavirus vaccine. India uses two pentavalent formulations approved by the Central Drugs Standard Control Organization (CDSCO): Panacea Biotec’s ‘EasyFive’ and SII’s ‘Quinvaxem’. Each contains 30 IU diphtheria toxoid, 40 IU tetanus toxoid, whole-cell pertussis (4 × 109 bacteria/mL), 10 µg HepB surface antigen, and 10 µg Hib polyribosylribitol phosphate (PRP) conjugated to tetanus toxoid. Doses are administered as 0.5 mL intramuscular injections in the anterolateral thigh. A 2022 study published in Indian Pediatrics confirmed that EasyFive demonstrated 94.7% seroprotection against Hib after three doses in rural Karnataka cohorts.
10-Week and 14-Week Doses: Completing the Primary Series
The second and third pentavalent doses follow at 10 weeks (±3 days) and 14 weeks (±3 days), respectively. OPV is co-administered each time — OPV type 1 (Maharashtra Biotech’s ‘Poliovac’) at 6 and 14 weeks, and OPV type 2 (SII’s ‘Biovac-2’) at 10 weeks. Rotavirus vaccination uses either Bharat Biotech’s ‘Rotavac’ (a single-strain G9P[11] vaccine requiring three oral doses at 6, 10, and 14 weeks) or SII’s ‘Rotasiil’ (pentavalent bovine-human reassortant, also three-dose). Notably, Rotavac must be administered before 16 weeks of age — the final dose cannot be given later than 14 weeks and 6 days per CDSCO mandate. Data from the 2023 National Family Health Survey (NFHS-6) shows 78.3% coverage for full rotavirus series in urban areas versus 62.1% in tribal districts of Chhattisgarh and Jharkhand.
Boosters and Newer Antigens: 9 to 18 Months
Between 9 and 18 months, children receive booster doses and newly introduced antigens designed to extend immunity and close serological gaps. At 9–12 months, Measles-Rubella (MR) vaccine replaces the older measles-only formulation nationwide. MR is delivered as a 0.5 mL subcutaneous injection using either SII’s ‘MR-Vac’ or Bio-Med’s ‘Rubevax’, both containing ≥ 1000 CCID50 of live attenuated measles virus (Schwarz strain) and ≥ 1000 CCID50 of rubella virus (Therien strain). The vaccine must be reconstituted with provided diluent and used within 4 hours at room temperature (≤25°C) or 8 hours if refrigerated. A 2023 evaluation by the Indian Council of Medical Research (ICMR) found MR-vaccinated children achieved 97.2% measles IgG seroconversion at 12 months — significantly higher than the 89.4% observed with monovalent measles in pre-2017 cohorts.
Pneumococcal Conjugate Vaccine (PCV) Rollout
PCV was introduced into India’s Universal Immunization Programme (UIP) in phases beginning January 2021 and achieved full national coverage by March 2023. Two formulations are deployed: PCV10 (Synflorix®, GSK) and PCV13 (Prevnar 13®, Pfizer). States select based on procurement cycles; Punjab and Kerala use Synflorix (covering serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F, 23F), while Maharashtra and Tamil Nadu administer Prevnar 13 (adds serotypes 3, 6A, 19A). The schedule mandates three primary doses at 6, 10, and 14 weeks, followed by a booster at 9–12 months. Each dose is 0.5 mL intramuscular. A landmark cohort study in Hyderabad (2022–2023) documented a 41% reduction in radiologically confirmed pneumonia hospitalizations among fully vaccinated toddlers versus unvaccinated controls.
Inactivated Polio Vaccine (IPV) Integration
IPV replaced fractional-dose IPV (fIPV) in all states effective October 2022. Children now receive one full 0.5 mL intramuscular dose at 14 weeks — co-administered with the third pentavalent and third OPV. The licensed product is SII’s ‘Polio-Full’, containing 40 D-antigen units of type 1, 8 D-antigen units of type 2, and 32 D-antigen units of type 3 poliovirus. Unlike OPV, IPV does not replicate in the gut and thus carries zero risk of vaccine-derived poliovirus (VDPV); however, it induces weaker mucosal immunity. Hence, the MoHFW mandates continued bivalent OPV (types 1+3) at 16–24 months and 5 years to maintain intestinal protection. Cold-chain compliance is stricter for IPV: it must be stored between +2°C and +8°C and discarded if exposed to temperatures >8°C for more than 72 cumulative hours.
Catch-Up Immunization Protocols
Missed or delayed vaccinations remain common — NFHS-6 reports 22.4% of Indian children aged 12–23 months have at least one overdue dose. The MoHFW’s ‘Catch-Up Immunization Guidelines (2023)’ provide precise rules: no dose needs repetition if administered ≥4 days before the minimum recommended age; however, doses given ≥5 days too early must be repeated after the correct interval. For example, if MR vaccine is mistakenly given at 8 months and 25 days (5 days before the 9-month minimum), it must be re-administered at or after 9 months. The minimum intervals between live vaccines (e.g., MR and Varicella) are 28 days; inactivated vaccines (e.g., DT, HepB) may be given simultaneously or at any interval.
The following table outlines standard catch-up rules for key antigens:
| Vaccine | Minimum Age for First Dose | Minimum Interval Between Doses | Maximum Age for Completion | Notes |
|---|---|---|---|---|
| BCG | Birth | Not applicable | 1 year | If missed, give up to 12 months; no repeat if positive Mantoux test |
| Pentavalent | 6 weeks | 4 weeks between doses | 6 months | Third dose must be completed by 26 weeks (6 months) |
| PCV | 6 weeks | 4 weeks between primary doses | 2 years | Children starting after 12 months need only 2 doses, 8 weeks apart |
| MR | 9 months | 28 days (if second dose required) | No upper limit | Second dose recommended at 16–24 months as part of MR campaign |
| Measles-containing vaccine (MCV) | 9 months | 28 days | 5 years | All children must receive ≥2 MCV doses by age 5 |
For children aged 2–5 years entering immunization programs late, the IAP recommends the following accelerated sequence: DT (not DTP) at 0 and 4 weeks, OPV at 0, 4, and 24 weeks, MR at 0 and 24 weeks, and PCV with two doses 8 weeks apart. Hepatitis B catch-up is indicated for all unvaccinated children under 19 years — three doses (0, 1, and 6 months) using 10 µg formulation for those <11 years or 20 µg for older adolescents.
Safety Monitoring and Adverse Event Reporting
Vaccine safety in India is governed by the Pharmacovigilance Programme of India (PvPI), which mandates reporting of all serious adverse events following immunization (AEFI) within 24 hours. Common minor reactions include low-grade fever (<38.5°C) in 12–18% of pentavalent recipients and mild injection-site induration in 22% after PCV. Severe AEFI — defined as events requiring hospitalization, causing disability, or resulting in death — occur at a rate of 0.78 per 100,000 doses administered (PvPI Annual Report 2023). Notably, anaphylaxis incidence is 1.2 per million doses for MR vaccine and 0.4 per million for PCV — lower than global averages reported to WHO’s VigiBase.
Parents are advised to monitor for specific red-flag symptoms post-vaccination:
- Fever >40°C persisting beyond 48 hours after any vaccine
- Convulsions with or without fever occurring within 72 hours of DT-containing vaccines
- Progressive bulging fontanelle or inconsolable crying >3 hours within 24 hours of pentavalent
- Respiratory distress or stridor within 4 hours of MR or PCV
- Any neurological symptom (e.g., ataxia, altered consciousness) within 14 days of MR
ASHA workers are trained to use the standardized AEFI triage card and refer immediately to the nearest Community Health Centre (CHC) equipped with adrenaline 1:1000, oxygen, and pediatric resuscitation kits. All CHCs maintain AEFI registers compliant with Form 10 of the Drugs and Cosmetics Rules, 1945.
Implementation Challenges and Equity Gaps
Despite progress, disparities persist. According to the 2023 National Health Profile, full immunization coverage (BCG, 3 DTP, 3 OPV, 1 MR, 1 HepBbirth, 3 PCV, 3 Rotavirus) stands at 76.4% nationally but drops to 41.2% among Scheduled Tribe children in Odisha and 38.9% among children in migrant construction-worker settlements in Delhi-NCR. Key barriers include: inconsistent cold-chain maintenance in remote PHCs (27% of assessed facilities had temperature excursions >8°C in Q1 2024), stockouts of Rotavac in 14 high-focus districts during monsoon months, and caregiver misconceptions — a 2023 ICMR qualitative study found 44% of mothers in Bihar believed ‘too many vaccines weaken the child’s immunity’.
To bridge these gaps, the MoHFW launched the ‘Mission Indradhanush 5.0’ in January 2024, focusing on 100 high-priority districts. Interventions include solar-powered cold boxes (Emkay SolarChill units, capacity 12 L, maintaining +2°C to +8°C for 120 hours without sunlight), real-time vaccine stock dashboards integrated with the CoWIN platform, and community engagement via ‘Vaccine Saathi’ peer educators trained in local dialects. Early results from Phase I (Jan–Jun 2024) show a 22.3% increase in on-time PCV3 coverage in Sundargarh district, Odisha, and a 31.6% decline in pentavalent default rates in East Siang, Arunachal Pradesh.
Resources for Families and Frontline Workers
Parents can access verified information through multiple government-approved channels. The ‘UMMID’ mobile app (available on Android and iOS) allows scanning of vaccine vial monitors (VVMs) to verify potency and displays personalized immunization calendars synced with birth registration data from the Civil Registration System. Printed materials include the bilingual ‘Child Health Handbook’ (English/Hindi), distributed free at all public health facilities, which features color-coded immunization trackers, growth charts, and QR codes linking to video demonstrations of proper injection techniques.
Frontline health workers rely on standardized job aids:
- The ‘Immunization Quick Reference Card’ (MoHFW Publication No. NIH/IMM/2023/QR-07), laminated and pocket-sized, listing maximum allowable delays per antigen
- The ‘Cold Chain Equipment Inventory Logbook’, mandating bi-hourly temperature entries for walk-in cold rooms and daily checks for ice-lined refrigerators
- The ‘AEFI Clinical Assessment Tool’, a 12-point checklist validated across 17 states for rapid field triage
- Digital training modules on the National Health Mission’s eLearning portal (courses NHM/IMM/2023/01–04), accredited for 8 CME credits
Additionally, pediatricians may consult the IAP’s freely accessible ‘Vaccine Handbook 2023’, now in its 7th edition, which includes revised guidance on co-administration with monoclonal antibodies (e.g., nirsevimab for RSV prophylaxis) and updated recommendations for immunocompromised children — such as avoiding live vaccines in those receiving ≥20 mg/day prednisolone for >14 days.
Accurate immunization records are non-negotiable. Every child’s vaccination must be entered into the Electronic Vaccine Intelligence Network (eVIN) within 24 hours of administration. eVIN integrates with the Ayushman Bharat Health Account (ABHA) number, enabling longitudinal tracking across facilities. As of June 2024, eVIN covers 37,241 functional cold chain points across 742 districts, with 99.3% data completeness for MR doses and 94.7% for PCV. Errors in recording — such as transposing digits in the ABHA ID or misclassifying ‘MR’ as ‘measles-only’ — directly impact dashboard accuracy and outbreak response readiness.
Vaccines are not merely biological agents — they are instruments of intergenerational equity. When a child in Ranchi receives her third dose of Rotavac, she gains not only protection against lethal dehydration but also uninterrupted school readiness. When a toddler in Leh receives PCV13, he avoids hearing loss linked to pneumococcal meningitis — preserving cognitive development pathways. India’s immunization schedule reflects decades of epidemiological rigor, operational learning, and ethical commitment. Its success hinges not on policy alone, but on the nurse who checks the VVM before drawing up DT, the ASHA who walks 5 km in monsoon rain to reach a hamlet without electricity, and the mother who returns for the 14-week visit despite harvest work — because she has been told, clearly and repeatedly, what each dose protects against, when it is due, and why timing matters down to the day.
The schedule is precise: BCG at birth, pentavalent at 6–10–14 weeks, MR at 9–12 months, PCV booster at 15–18 months, and DPT and OPV boosters at 16–24 months and 5 years. It is also adaptable: catch-up rules exist, alternative brands are prequalified, and safety nets like AEFI surveillance are institutionalized. What remains essential is consistent translation of this precision into practice — one dose, one child, one community at a time.
For real-time updates, healthcare providers should consult the MoHFW’s official UIP portal (https://uip.gov.in) and cross-check with the latest IAP ACVIP bulletin (Bulletin No. 23/2024, issued 15 April 2024). Parents are encouraged to download the ‘HealthTrack India’ app, where entering a child’s date of birth and gender auto-generates a state-specific immunization calendar compliant with both NIS and IAP harmonized schedules.
Every vaccine vial carries a responsibility — to deliver exactly the right antigen, at exactly the right time, in exactly the right condition. In India’s diverse, dynamic landscape, that responsibility is met not through uniformity, but through context-aware science, human-centered delivery, and unwavering accountability at every node of the system.
As of July 2024, the next scheduled revision of the NIS will incorporate new evidence on maternal Tdap immunization (currently piloted in 12 districts), updated typhoid conjugate vaccine (TCV) dosing for children aged 6 months to 5 years, and expanded HPV vaccination for girls aged 9–14 years using Cervavac (Bharat Biotech), India’s first indigenously developed quadrivalent HPV vaccine licensed in December 2023.
Reliable immunization is not an event — it is a continuum of care anchored in trust, data, and daily dedication. From the neonatal ward in AIIMS New Delhi to the outreach session in a Nagaland village, the schedule remains the same: a living document, rigorously tested, compassionately delivered, and relentlessly refined.
